Professor Robin J Shattock

Robin is the Professor of Mucosal Infection and Immunity, leading a team of 25 researchers within the Department of Medicine. The main focus of his research is the investigation of the mechanisms of mucosal HIV transmission and development of novel preventative strategies appropriate to a developing world setting. This has led to the establishment of international collaborations aimed at preclinical identification, development and selection of microbicide and vaccine candidates prior to formal clinical efficacy trials.

Robin has secured funding from the Wellcome Trust, NIH, European Commission, and the Bill and Melinda Gates Foundation. He currently holds a Grand Challenges for Global Health Initiative program grant to optimize vaginal vaccination against HIV infection co-funded by the Wellcome Trust and The Bill and Melinda Gates Foundation. Robin also leads the Mucosal Discovery Team for CHAVI-ID, the Center for HIV AIDS Vaccine Immunology and Immunogen Discovery funded by NIH. In addition, he coordinates the EUROPRISE Network of Excellence on Vaccines and Microbicides that coordinates EU funded research in this area across 40 institutions. He provides scientific coordination for European Microbicide program CHAARM (Combined Highly Active Anti-Retroviral Microbicides) and EMPRO.

Robin chairs the WHO-UNAIDS HIV Vaccine Initiative Advisory Committee, the Research and Advisory Steering Committee of the International Partnership for Microbicides and is a member of the Scientific Advisory boards of the International Aids Vaccine Initiative (IAVI), Global HIV Vaccine Enterprise Scientific Committee (GHVE), the South African AIDS Vaccine Initiative SAAVI, the Scientific Advisory Board Review of the ANRS HIV Vaccine Research Program, and the Chinese Aids Vaccine Initiative (CAVI). Robin is on the editorial board of Mucosal Immunology and AIDS Research and Human Retroviruses and is an elected Fellow of the Society for Biology.